{"name":"Pharming Group","slug":"pharming","ticker":"PHARM.AS","exchange":"Euronext Amsterdam","domain":"pharming.com","description":"Pharming Group is a biopharmaceutical company focused on rare diseases. Its key products include Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema, and Jevtana, a chemotherapy medication for prostate cancer. The company operates in a niche market with a limited number of competitors.","hq":"Leiden, Netherlands","founded":1988,"employees":"~350","ceo":"Sijmen de Vries","sector":"Rare Disease / Biopharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":280000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2023-01-01","label":"Joenja first approved","drug":"Joenja","drugSlug":"leniolisib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Ruconest patent cliff ($0.0B at risk)","drug":"Ruconest","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-01","label":"Jevtana patent cliff ($0.0B at risk)","drug":"Jevtana","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Joenja","genericName":"LENIOLISIB","slug":"leniolisib","indication":"Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)","status":"marketed"},{"name":"Ruconest","genericName":"CONESTAT ALFA","slug":"conestat-alfa","indication":"Hereditary C1 esterase inhibitor deficiency - deficient factor","status":"marketed"}]}],"pipeline":[{"name":"Joenja","genericName":"LENIOLISIB","slug":"leniolisib","phase":"marketed","mechanism":"Joenja works by blocking the activity of a specific enzyme called PI3K delta, which is involved in the immune system's response.","indications":["Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)"],"catalyst":""},{"name":"Ruconest","genericName":"CONESTAT ALFA","slug":"conestat-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary C1 esterase inhibitor deficiency - deficient factor"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Pharming Group reports 2023 full-year results","summary":"Pharming Group reported a net loss of €44.8 million for 2023, compared to a net loss of €53.1 million in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-06-01","type":"deal","headline":"Pharming Group and UCB announce collaboration on rare disease treatments","summary":"Pharming Group and UCB announced a collaboration to develop and commercialize treatments for rare diseases.","drugName":"","sentiment":"positive"},{"date":"2022-03-31","type":"regulatory","headline":"Pharming Group receives FDA approval for Ruconest","summary":"Pharming Group received FDA approval for Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQeTZWRHRXVzRPOElHbWc0MGs4M21vQ1dtSklyenA1ZWRsSHFIUnlyS05HZUN4bEowaHUzMHlCZ01hZWUxSW5xZk9VMENjUi1iQ1ZUTGFOWEFhTDJia0J1ZmxsbmRmVm1CR1NaYnI3U3BHWUo1Nmdsc3NIem5SeGMwZTRGaGdGQVVWMTBqTXh3?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharming Group announces the filing of its 2025 Annual Report and Form 20-F - Yahoo Finance UK","headline":"Pharming Group announces the filing of its 2025 Annual Report and Form 20-F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPUFZNQURqQzRkRC1Ua3kwMUNWWHB0d282ejg2SjlPNW1FQXdVVm81SUF0QXNfSWFWMzJtNHF0cUxWYklOOHRISndrYTctbThIZHk4c2l0cnhEbU9uaTliQ3RkT09kRmhUb19odFFHTVNYMlhCb3NBQWc5MmZYM1QzdFNsS1NnNXZvY3NxYXpuWQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older - Yahoo Finance UK","headline":"Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5YRGhKLXNhRmI2eEtvb09tazB5VXhEcVRsdmJTd1lyUzdUZUlwV0lUakl5bVJ5YzkyODBMajV0VHNrcjNWS0VibzhUSy1obDBfQ0ZtZHhTQmY3azd4ZTIybjNVVmg?oc=5","date":"2026-03-20","type":"pipeline","source":"ChartMill","summary":"PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill","headline":"PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"earnings","source":"simplywall.st","summary":"Pharming Group (ENXTAM:PHARM) Returns To Profitability Challenging Cautious Earnings Narratives - simplywall.st","headline":"Pharming Group (ENXTAM:PHARM) Returns To Profitability Challenging Cautious Earnings Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPRldMOE9pcTNaWVR0Tl93dGE4RXl5eFJLOWdDYmZHVEZQdWV0Mzc4dUxRMEs5aGkwQ0gwRlRncThQUmRZNXhESWlIcmswN3ZzalNkaTJYTzBmUEYtS2JIeHhuZDhJZFFoeEpyRmFITS02a3dJcXpzYjBkanZhNEtqY25mZk1yUV9UQmQzM0QyNWIyWUl6ZTQwWS0zMkMtLXQyTFc4dUNsdThNT08zVU80Sm9ReWp5TnhTV2JFNW9oQzZkS1E?oc=5","date":"2026-03-12","type":"earnings","source":"Idéal Investisseur","summary":"Pharming Group: Revenue Up 27%, 1,800 Patients Could Change Everything - Idéal Investisseur","headline":"Pharming Group: Revenue Up 27%, 1,800 Patients Could Change Everything - Idéal Investisseur","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxObGRWM2FtRTIta3Z0NGJnckN6X1lWVkNReFBQaTVDel9DQWpta2w4UW9mU1ZZZ0xreVZLajFfTEhraEhfVk11a05sdTZIUXdOOU8zY1lDN20tYWJtLUxsdnZSZG95dDR4bHdpQ0lHNENrcUVWWjFDQ1ZvQ0RHanhnbGxZd0NrQ18xWmhHM3BLZEg?oc=5","date":"2026-02-02","type":"regulatory","source":"The Pharma Letter","summary":"FDA slaps CRL on Pharming’s sNDA for Joenja - The Pharma Letter","headline":"FDA slaps CRL on Pharming’s sNDA for Joenja","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPR2lXSTR2V2hGbUlGa0ZZRnpJbDl2b096UTI5blBuUW9taVlyRFNnR2N2a25hemM4UlV3SjRJWktvYlJyYTJEWlh3TnFmWjlYODB5eU9IdFI0bERfRjcxQUNZYzZUa2tUNUxfMWd5Y2xuaHYxV2wzcjdpSzFjSm95anFOcjFyelhwVUYtQjJvRnV2Zw?oc=5","date":"2026-02-02","type":"pipeline","source":"Yahoo Finance UK","summary":"Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day - Yahoo Finance UK","headline":"Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQTWNPaVR5eEQxV1JieXN0aXVJV0VYbWRsYlFqWHNRSERqQ1BJS2tua0VNMDJPcWk0amRtT1RFM3RPc3RYVzBQVGROZGFocGo4WXQ4VVM0OHo5YWNrRDNmeV8zVnp1TGZjclNMa04xeWRLRTZ4TnRQNm10NDRjY3dUWTRB?oc=5","date":"2026-02-02","type":"regulatory","source":"pharmaphorum","summary":"FDA knocks back Pharming's bid for wider Joenja use - pharmaphorum","headline":"FDA knocks back Pharming's bid for wider Joenja use","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNNzN1aDl2OE9FeTVWUjU0SHh5Y2dpUGhvbVZJR0dad29YMmdON3lRVHQ5RjZvbTdtQVRNRHRjbmFOdllIeVYzbDdHcnp4M3h2ZXFTaFlSYXBKNkxsT3U3MWhENjQza1IwT19fcW5uSlUzMjZwSDFtNkR1NHpZVF82SUZvZ1Zod0JUVHZrNmtjX3VIdmNFNVNIMF92WklkcnVWUWdsSTlvejJGZWdhX1E0?oc=5","date":"2026-01-22","type":"pipeline","source":"Idéal Investisseur","summary":"Pharming Group Shares Surge 11.33% at Thursday's Close - Idéal Investisseur","headline":"Pharming Group Shares Surge 11.33% at Thursday's Close - Idéal Investisseur","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-08","type":"pipeline","source":"simplywall.st","summary":"Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement - simplywall.st","headline":"Pharming Group N.V. (AMS:PHARM) Surges 26% Yet Its Low P/S Is No Reason For Excitement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOQ3RYQVdGMWIwaXBHTTdSZmVvQnoxeEJiY3FvN0U2bV9WYy1XN0VCSDN4amVjdExhS2hoR2I5UUlEZ0g5LW1tM0lzRVRJNHpFYmItRmtQTk5mMmR6Yk52djdPczBuNDVsUmN2QUI2VFBzamNOTmpOSXpyQzlTV2twQ1EzNy1CSzI5Z09CT3lsYm4tdFFiMl9xZFpRMS1QVnlTdDFxTTc5RW9JaXJPcllYRi1HQVJGLVo1UnRRUUltanAyS3k0c1p3Z3EybTRYV0hVZGMyZGt5UmNaUS0zUjd1Qlh2M2pZZ1dlbGI0VTJn?oc=5","date":"2025-01-21","type":"pipeline","source":"BioSpace","summary":"Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer - BioSpace","headline":"Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNdm0tOEFQZDZwYW9hdGRvdXRDUjJmN1BlWVNwS3BPYlpzZmVEb29sc2w5YVI3RWhNM3JVSWlzbExidXVDYjFiVnpxNlRFSmVxV1h1WjEtQjRfb2pyRTNfY0F5blg3WnBtYV9ZdDR4eTlnVC1xTEdpRE9VQ2s3bG5rcXhFazlmMm1WMlZxUkVsRE9CQnB0SFBwbTZB?oc=5","date":"2023-03-27","type":"regulatory","source":"Fierce Pharma","summary":"With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug - Fierce Pharma","headline":"With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug","sentiment":"neutral"}],"patents":[{"drugName":"Ruconest","drugSlug":"c1-esterase-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"Jevtana","drugSlug":"cabazitaxel","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Shire","Biogen","Sanofi"],"therapeuticFocus":["Rare diseases","Oncology"],"financials":null,"yahoo":null}